SGO

Overall risk and risk of endometrioid subtype 20- to 30-fold greater in women younger than 35

Adding immunotherapy will change frontline treatment, experts say

High response rates in small studies of immuno-oncology combination, neoadjuvant olaparib

Long-running clinical trial failed to identify any subgroup that fared better with CRT

Pathologic response rises to 73% versus 50% in historical control group

Responses in a fourth of patients, clinical benefit in up to 90%

Should the gynecologic oncology community reconsider IP therapy?

Final analysis of LACC trial confirms earlier findings

Presenter breaks news at SGO that drug developer commits to overhauling dose reduction program

Benefit was greatest among patients with wild-type p53 cancer in SIENDO trial

Ocular AEs an issue with mirvetuximab in folate receptor alpha-high platinum-resistant disease

PRO-based analysis of KEYNOTE-826 trial shows favorable benefit-risk ratio

Study suggests no improvement in overall survival

Key factors predicted threefold higher risk of 90-day mortality with primary surgery